Edgar Filing: BIENAIME JEAN JACQUES - Form 4

BIENAIME Form 4 March 28, 2	E JEAN JACQUE 2018	S								
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB APPROVAL	
	UNITED	STATES SE	CURITIES . Washingtor				COMMISSIO	N OMB Numbe	r: 3235-0287	
Check t if no los	ngar		U					Expires	January 31,	
subject Section Form 4	to SIAIE	STATEMENT OF CHANGES IN BENEFICIAL OWNERS SECURITIES							2005 ed average hours per se 0.5	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> BIENAIME JEAN JACQUES			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			C [BMRN]							
(Last)	(First)		Date of Earliest T	Fransaction	1		X Director X Officer (g	ive title	10% Owner Other (specify	
C/O BIOM PHARMA LINDARC	CEUTICAL INC	03/	(Month/Day/Year) 03/26/2018				below) below) Chief Executive Officer			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
	AEL, CA 94901						Form filed by Person	More than Or	ne Reporting	
(City)	(State)	(Zip)	Table I - Non-	Derivativ	e Secu	irities Ac	quired, Disposed	of, or Benef	icially Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Ye	Code	on(A) or Di (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/26/2018	03/26/2018	М	1,000	A	\$ 14.39	285,031	D		
Common Stock	03/27/2018	03/27/2018	М	1,000	А	\$ 14.39	286,031	D		
Common Stock							182,201	I	Shares held by Jean-Jacques Bienaime Family Trust	

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy Common Stock)	\$ 14.39	03/26/2018	03/26/2018	М	1,000	11/12/2009	05/11/2019	Common Stock	1,000
Stock Option (Right to buy Common Stock)	\$ 14.39	03/27/2018	03/27/2018	М	1,000	11/12/2009	05/11/2019	Common Stock	1,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	Х		Chief Executive Officer				
Signatures							
/s/ Laura Randall Woodhead, Attorney-in-Fact		8/2018					
<u>**</u> Signature of Reporting Person	D	ate					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.